Prokaryotics
Prokaryotics Inc. is an authentic antibacterial discovery organization committed to bringing forth innovative therapeutics to address the problem of multidrug resistant bacteria and combating the emerging global crisis of antibiotic resistance. The company leverages deep knowledge of bacterial physiology, innovative screening strategies, and medicinal chemistry expertise to develop new classes of antibiotics targeting bacterial cell envelope biogenesis, aiming to treat serious multi-drug resistant bacterial infections.
Industries
Nr. of Employees
small (1-50)
Prokaryotics
1075 Morris Avenue, Union, NJ 07083
Products
Novel Antibiotic Development Programs
Prokaryotics is engaged in the development of new classes of antibiotics targeting both Gram-negative and Gram-positive bacteria, focusing on cell envelope biogenesis.
Antibacterial Discovery and Development
The company utilizes innovative screening strategies and medicinal chemistry to discover and develop antibiotics.
Mechanistically Novel Agents for Fungal Infections
Prokaryotics has received funding to develop novel agents to treat drug-resistant fungal infections.
Cell Envelope Targeting Gram-negative Antibiotics
Development of small molecule inhibitors targeting MsbA-mediated transport and biogenesis of lipopolysaccharide in Gram-negative bacteria.
Bacterial Cell Wall Inhibitor Development
Working on a bacterial cell wall inhibitor in combination with polymyxin cell envelope permeabilizers to treat A. baumannii infections.
β-lactam Potentiator Program
Developing compounds to restore the efficacy of β-lactams against MRSA by targeting specific bacterial mechanisms.
Novel Antibiotic Development Programs
Prokaryotics is engaged in the development of new classes of antibiotics targeting both Gram-negative and Gram-positive bacteria, focusing on cell envelope biogenesis.
Antibacterial Discovery and Development
The company utilizes innovative screening strategies and medicinal chemistry to discover and develop antibiotics.
Mechanistically Novel Agents for Fungal Infections
Prokaryotics has received funding to develop novel agents to treat drug-resistant fungal infections.
Cell Envelope Targeting Gram-negative Antibiotics
Development of small molecule inhibitors targeting MsbA-mediated transport and biogenesis of lipopolysaccharide in Gram-negative bacteria.
Bacterial Cell Wall Inhibitor Development
Working on a bacterial cell wall inhibitor in combination with polymyxin cell envelope permeabilizers to treat A. baumannii infections.
β-lactam Potentiator Program
Developing compounds to restore the efficacy of β-lactams against MRSA by targeting specific bacterial mechanisms.
Services
Research programs to discover new classes of antibiotics that disrupt bacterial cell envelope assembly.
Hit-to-lead campaigns, SAR-driven optimization, and lead progression toward preclinical candidates.
Development of in vitro and whole-cell assays, and support for HTS and medicinal chemistry profiling.
Selection of preclinical candidates and evaluation of in vivo efficacy using animal infection models and translational modeling.
Design and preclinical development of combination products and potentiators to enhance or restore antibiotic activity.
In‑licensing of early-stage antibiotic assets and management of partnerships to advance preclinical programs toward commercialization.
Research programs to discover new classes of antibiotics that disrupt bacterial cell envelope assembly.
Hit-to-lead campaigns, SAR-driven optimization, and lead progression toward preclinical candidates.
Development of in vitro and whole-cell assays, and support for HTS and medicinal chemistry profiling.
Selection of preclinical candidates and evaluation of in vivo efficacy using animal infection models and translational modeling.
Design and preclinical development of combination products and potentiators to enhance or restore antibiotic activity.
In‑licensing of early-stage antibiotic assets and management of partnerships to advance preclinical programs toward commercialization.
Expertise Areas
- Antibiotic discovery targeting cell envelope/outer membrane biogenesis
- Medicinal chemistry lead identification and optimization
- Phenotypic and high-throughput screening
- Assay development and profiling
Key Technologies
- Phenotypic screening
- High-throughput screening (HTS)
- Whole-cell antibacterial assays
- In vitro biochemical and cellular assays